Compare ADMA Biologics Inc (ADMA) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Kinross Gold Corporation — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Kinross Gold Corporation trades at $27.49 (market cap $32.29B). The key difference: Kinross Gold Corporation is far larger — about 14.5× ADMA Biologics Inc's market cap, and Kinross Gold Corporation pays a 0.59% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | KGC | |
|---|---|---|
Market Cap | $2.22B | $32.29B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $38.06 |
52-Week Low | $7.60 | $18.70 |
Enterprise Value | $2.29B | $30.37B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
Kinross Gold (KGC) trades at $27.70, up 1.09% today, with a bullish technical signal from moving averages but overbought RSI levels. The company demonstrates robust fundamentals, with Q2 2026 EPS beating estimates at $0.71 versus $0.66 expected, and strong cash flow growth, with 2025 operating cash flow at $3.76 billion. Recent news includes a credit rating upgrade to 'BBB' by S&P Global Ratings on August 6, 2026, and ongoing project developments like Lobo-Marte.
The outlook is positive, supported by earnings beats, rising gold prices, and a consensus price target of $37.20, implying 34% upside. Risks include cost pressures and gold price volatility, but institutional buying and a 58.6% analyst buy rating suggest confidence in continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
